Scientific Publications
20
Feb
2023
“CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial” published in “The Lancet Haematology”.
05
Oct
2022
Clinical Grade Manufacture of CYAD-101, a NKG2D-based, First in Class, Non–Gene-edited Allogeneic CAR T-Cell Therapy
25
Jan
2022
KEYNOTE-B79 Phase 1b trial to evaluate the allogeneic CAR T-cells CYAD-101 and pembrolizumab in refractory metastatic colorectal cancer patients
13
Dec
2021
Update from ASH: Data from CYAD-02 CYCLE 1 Phase 1 study and CYAD-211 IMMUNICY-1 Phase 1 study
13
Dec
2021
IMMUNICY-1: Targeting BCMA with CYAD-211 to Establish Proof Of Concept of An shRNA-based Allogeneic CAR T-cell Therapy Platform
12
Nov
2021
Armoring NKG2D-based CAR T cells with IL-18 improves in vitro and in vivo anti-tumor activity
12
Nov
2021
A Phase 1b KEYNOTE-B79 trial evaluating non-gene edited allogeneic CAR T-cells, CYAD-101, post FOLFOX preconditioning, followed by pembrolizumab, in refractory metastatic colorectal cancer patients
11
Jun
2021
Objective response at low dose in the first-in-human IMMUNICY-1 trial evaluating non-gene edited allogeneic CYAD-211 anti-BCMA CAR T product in relapsed or refractory multiple myeloma
11
Jun
2021
Update from EHA – Preliminary Data from Phase 1 IMMUNICY-1 Trial of shRNA-based Allogeneic CAR T Candidate CYAD-211 in r/r MM
15
Jan
2021
ASCO GI: Updated Data from the alloSHRINK Phase 1 First-in-Human Study Evaluating CYAD-101, an Innovative Non-Gene-Edited Allogeneic CAR-T, in Metastatic Colorectal Cancer
24
Dec
2020
Hairpins and Scissors – Delivering a Non-Gene Edited Allogeneic CAR T Cell Therapy for the Masses
05
Dec
2020
ASH: Results from the Phase I Clinical Studies Evaluating CYAD-01, a first-generation NKG2D CAR T-cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients
05
Dec
2020
ASH: Clinical Development of a Non-Gene-Edited Allogeneic BCMA-Targeting CAR T-cell Product in Relapsed or Refractory Multiple Myeloma
05
Dec
2020
ASH: First Results from the Dose Escalation Segment of the Phase I Clinical Study Evaluating CYAD-02, an Optimized Non-Gene-Edited Engineered NKG2D CAR T-cell Product, in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients
29
May
2020
ASCO: Single vector multiplexed shRNA provides a non-gene edited strategy to concurrently knockdown the expression of multiple genes in CAR T-cells
29
May
2020
ASCO: CYAD-101, an innovative non-gene edited allogeneic CAR-T for solid tumor cancer therapy
09
Dec
2019
Results from the completed dose escalation of the hematological arm of the phase I THINK study evaluating multiple infusions of NKG2D-based CAR T-cells as standalone therapy in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome patients
09
Dec
2019
Interim results from the phase I DEPLETHINK trial evaluating the infusion of a NKG2D CAR T-cell therapy post a non-myeloablative conditioning in relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome patients
09
Dec
2019
Next generation NKG2D-based CAR-T cells (CYAD-02): Co-expression of a single shRNA targeting MICA and MICB improves cell persistence and anti-tumor efficacy in vivo
09
Nov
2019
Results from the completed dose-escalation of the ALLOSHRINK phase I study evaluating the allogeneic NKG2D-based CAR T-cell therapy CYAD-101 in metastatic colorectal cancer patients
09
Nov
2019
Results from the completed dose-escalation phase I SHRINK study evaluating the autologous NKG2D-based CAR T-cell therapy CYAD-01 in metastatic colorectal cancer patients
09
Nov
2019
Effect of chemotherapy on cellular kinetics of NKG2D-based CAR T-cells in metastatic colorectal cancer patients
09
Nov
2019
The targeted knockdown of CD3ζ by shRNA as a platform to develop allogeneic CAR T cell therapy
16
Sep
2019
The targeted knockdown of CD3ζ by shRNA as a platform to develop allogeneic CAR T cell therapy
16
Sep
2019
Understanding the expression profile of NKG2D ligands on T cells: Implications for CAR T cell therapy
05
Jul
2019
Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR T therapy in metastatic colorectal cancer
15
Jun
2019
DEVELOPMENT OF A NEXT GENERATION ALLOGENEIC CAR-T CELL PLATFORM WITHOUT GENE EDITING
15
Jun
2019
Updated results from Phase I trials assessing a NKG2D CAR T-cell approach in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome patients
18
May
2019
NKG2D as a chimeric antigen receptor – DAP10 provides optimal co-stimulation for NKG2D-based CARs
18
May
2019
NKG2D as a chimeric antigen receptor – DAP10 provides optimal co-stimulation for NKG2D-based CARs
03
Dec
2018
Remissions in Relapse/Refractory Acute Myeloid Leukemia Patients Following Treatment with NKG2D CAR-T Therapy Without a Prior Preconditioning Chemotherapy
03
Dec
2018
Interim results from the phase I DEPLETHINK trial evaluating the infusion of a NKG2D CAR T-cell therapy post a non-myeloablative conditioning in relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome patients
03
Dec
2018
Results from the completed dose escalation of the hematological arm of the phase I THINK study evaluating multiple infusions of NKG2D-based CAR T-cells as standalone therapy in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome patients
03
Dec
2018
Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-based CAR-T Therapy, CYAD-01, in Acute Myeloid Leukemia
18
Nov
2018
CYAD-101: an allogeneic NKG2D CAR T cell therapy using a TCR inhibitory molecule
18
Nov
2018
Uncovering the phenotype, functional and homing properties of NKG2D CAR T cells
18
Nov
2018
The co-expression of a single shRNA targeting MICA and MICB with a NKG2D CAR generates CAR-T cells resistant to target driven fratricide and improves CAR T cell persistence in vivo
09
Nov
2018
Results and perspectives from Phase 1 studies assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, CYAD-01, in metastatic solid tumors
19
Oct
2018
Tackling fratricide to manufacture clinical grade NKG2D‐CAR T cells for cancer therapy
19
Oct
2018
Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-based CAR-T Therapy, CYAD-01, in Metastatic Colorectal Cancer
19
Oct
2018
The high expression of NKG2D ligands on tumor and non‐tumor cells and a lack of surface expression on healthy tissues provide a strong rationale to support NKG2D‐based therapeutic approaches for cancer.
01
Jul
2018
Manufacturing development and clinical production of NKG2D chimeric antigen receptor–expressingT cells for autologous adoptive cell therapy
19
May
2018
Early signs of clinical activity of NKG2D CAR-T cell (CYAD-01) activity in AML patient
16
May
2018
Expression of a TIM peptide reduces alloreactivity of T cells facilitating an allogeneic NKG2D Chimeric Antigen Receptor T cell therapy approach
27
Apr
2018
NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient
17
Apr
2018
The THINK clinical trial: Preliminary evidence of clinical activity of NKG2D Chimeric Antigen Receptor T cell therapy (CYAD-01) in acute myeloid leukemia
17
Apr
2018
NKG2D as a chimeric antigen receptor – DAP10 provides optimal co-stimulation for NKG2D-based CARs
17
Apr
2018
A Phase 1 study assessing the safety and clinical activity of multiple doses of an NKG2D-based CAR-T therapy, CYAD-01, administered concurrently with neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer
17
Apr
2018
A Phase 1 study assessing the safety and clinical activity of multiple hepatic transarterial administrations of an NKG2D-based CAR-T therapy, CYAD-01, in patients with unresectable liver metastases from colorectal cancer
14
Nov
2017
Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types
01
Sep
2017
A Phase I Global Trial Targeting Multiple Solid and Hematologic Malignancies through a NKG2D receptor-based CAR-T Immunotherapy
01
Aug
2017
‘Atypical’ CAR T cells: NKG2D and Erb-B as examples of natural receptor/ligands to target recalcitrant solid tumors
05
Jun
2017
A NKG2D-based CAR-T therapy in a Multinational Phase 1 Dose Escalation and Expansion Study Targeting Multiple Solid and Hematologic Tumor Types
06
Dec
2016
Safety Data from a First-in-Human Phase I Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma
13
Sep
2016
Safety Data from a First-in-Human Phase I Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma
04
Jun
2016
A First-in-Human Phase I Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma